Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Adma Biologics (ADMA) over the last 5 years, with Dec 2024 value amounting to $243.3 million.

  • Adma Biologics' Shares Outstanding (Diluted Average) rose 0.28% to $245.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.5 million, marking a year-over-year increase of 0.28%. This contributed to the annual value of $243.3 million for FY2024, which is 8.65% up from last year.
  • Adma Biologics' Shares Outstanding (Diluted Average) amounted to $243.3 million in FY2024, which was up 8.65% from $224.0 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Shares Outstanding (Diluted Average) ranged from a high of $243.3 million in FY2024 and a low of $86.1 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $224.0 million (2023), whereas its average is $221.7 million.
  • Data for Adma Biologics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 62.03% (in 2021) over the last 5 years.
  • Adma Biologics' Shares Outstanding (Diluted Average) (Yearly) stood at $86.1 million in 2020, then spiked by 62.03% to $139.6 million in 2021, then surged by 41.77% to $197.9 million in 2022, then grew by 13.19% to $224.0 million in 2023, then increased by 8.65% to $243.3 million in 2024.